Kiniksa Pharmaceuticals International (KNSA) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$79.78
+1.3% on the day
+109.3% over 12 months
52-week range $37.01 – $80.92
Share price and insider trades
KNSA closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$60.3M
Insiders buying0
Insiders selling8
Kiniksa Pharmaceuticals International insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $60.3M of KNSA stock on the open market.
Get emailed when insiders cluster-buy stocks like KNSA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
KNSA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $668K | 2 |
| Q2 2026 | — | 0 | $34.0M | 15 |
| Q1 2026 | — | 0 | $5.6M | 13 |
| Q4 2025 | — | 0 | $20.0M | 17 |
| Q3 2025 | — | 0 | $1.6M | 1 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Kiniksa Pharmaceuticals International, plc insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $60.3M. 47 of 48 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 3SEC | Michael R MegnaChief Accounting Officer | Sell Plan | 4,60029,062 held (−14%) | $80.30 | $369K | -0.6% | — |
| Jul 31SEC | G Bradley ColeDirector | Sell | 3,67311,672 held (−24%) | $81.43 | $299K | -2.0% | — |
| May 5SEC | John F. PaoliniChief Medical Officer | Sell Plan | 37,32786,720 held (−30%) | $53.52 | $2.0M | +49.1% | — |
| May 5SEC | John F. PaoliniChief Medical Officer | Sell Plan | 21,09765,623 held (−24%) | $54.04 | $1.1M | +47.6% | — |
| May 1SEC | Sanj K PatelCEO, Chair | Sell Plan | 48,565 | $54.02 | $2.6M | +47.7% | — |
| Apr 30SEC | Sanj K PatelCEO, Chair | Sell Plan | 243,59651,750 held (−82%) | $52.02 | $12.7M | +53.4% | — |
| Apr 30SEC | Sanj K PatelCEO, Chair | Sell Plan | 113,673295,346 held (−28%) | $51.47 | $5.9M | +55.0% | — |
| Apr 30SEC | Sanj K PatelCEO, Chair | Sell Plan | 74,635409,019 held (−15%) | $50.43 | $3.8M | +58.2% | — |
| Apr 30SEC | Sanj K PatelCEO, Chair | Sell Plan | 51,750 | $54.02 | $2.8M | +47.7% | — |
| Apr 30SEC | Sanj K PatelCEO, Chair | Sell Plan | 22,544 | $54.01 | $1.2M | +47.7% | — |
| Apr 30SEC | Sanj K PatelCEO, Chair | Sell Plan | 2,141 | $54.01 | $116K | +47.7% | — |
| Apr 29SEC | Barry D QuartDirector | Sell Plan | 13,09912,546 held (−51%) | $50.10 | $656K | +59.2% | — |
| Apr 13SEC | Michael R MegnaChief Accounting Officer | Sell Plan | 6,62527,418 held (−19%) | $46.69 | $309K | +70.9% | — |
| Apr 13SEC | Ross MoatCOO | Sell Plan | 1,70312,029 held (−12%) | $46.69 | $80K | +70.9% | — |
| Apr 8SEC | Sanj K PatelCEO, Chair | Sell Plan | 7,278 | $50.01 | $364K | +59.5% | — |
| Apr 8SEC | Barry D QuartDirector | Sell Plan | 6,90112,546 held (−35%) | $50.00 | $345K | +59.6% | — |
| Apr 8SEC | Ross MoatCOO | Sell Plan | 2,36712,029 held (−16%) | $48.58 | $115K | +64.2% | — |
| Mar 11SEC | Mark RagosaCFO | Sell Plan | 18,74112,086 held (−61%) | $46.24 | $867K | +72.5% | — |
| Mar 11SEC | Mark RagosaCFO | Sell Plan | 17,98130,827 held (−37%) | $45.58 | $820K | +75.0% | — |
| Mar 4SEC | John F. PaoliniChief Medical Officer | Sell Plan | 22,22367,038 held (−25%) | $44.88 | $997K | +77.8% | — |
| Mar 4SEC | John F. PaoliniChief Medical Officer | Sell Plan | 12,06389,261 held (−12%) | $44.20 | $533K | +80.5% | — |
| Mar 4SEC | John F. PaoliniChief Medical Officer | Sell Plan | 5,71461,324 held (−9%) | $45.92 | $262K | +73.7% | — |
| Feb 12SEC | Barry D QuartDirector | Sell Plan | 2,69012,546 held (−18%) | $45.00 | $121K | +77.3% | — |
| Feb 12SEC | Barry D QuartDirector | Sell Plan | 11012,546 held (−1%) | $45.00 | $5K | +77.3% | — |
| Feb 11SEC | Mark RagosaCFO | Sell Plan | 9,11420,817 held (−30%) | $42.85 | $391K | +86.2% | — |
| Feb 11SEC | Mark RagosaCFO | Sell Plan | 8,73112,086 held (−42%) | $43.72 | $382K | +82.5% | — |
| Feb 4SEC | Barry D QuartDirector | Sell Plan | 12,52812,546 held (−50%) | $45.27 | $567K | +76.2% | — |
| Feb 4SEC | Barry D QuartDirector | Sell Plan | 2,60212,546 held (−17%) | $45.02 | $117K | +77.2% | — |
| Feb 4SEC | Barry D QuartDirector | Sell Plan | 83012,546 held (−6%) | $45.00 | $37K | +77.3% | — |
| Jan 9SEC | Mark RagosaCFO | Sell Plan | 12,00019,086 held (−39%) | $41.89 | $503K | +90.5% | — |
| Dec 17SEC | Barry D QuartDirector | Sell Plan | 20,12912,546 held (−62%) | $41.51 | $836K | +92.2% | — |
| Dec 17SEC | Eben TessariCOO | Sell Plan | 12,04816,666 held (−42%) | $41.56 | $501K | +92.0% | — |
| Dec 10SEC | Mark RagosaCFO | Sell Plan | 42,84131,086 held (−58%) | $41.49 | $1.8M | +92.3% | — |
| Dec 1SEC | Eben TessariCOO | Sell Plan | 20022,714 held (−1%) | $42.89 | $9K | +86.0% | — |
| Nov 19SEC | Eben TessariCOO | Sell Plan | 11,82522,714 held (−34%) | $41.30 | $488K | +93.2% | — |
| Nov 19SEC | Eben TessariCOO | Sell Plan | 64534,539 held (−2%) | $40.08 | $26K | +99.1% | — |
| Nov 14SEC | Mark RagosaCFO | Sell Plan | 19,90031,086 held (−39%) | $40.94 | $815K | +94.9% | — |
| Nov 4SEC | John F. PaoliniChief Medical Officer | Sell Plan | 82,54261,324 held (−57%) | $37.14 | $3.1M | +114.8% | — |
| Oct 30SEC | Mark RagosaCFO | Sell Plan | 10031,086 held (−0%) | $41.00 | $4K | +94.6% | — |
| Oct 22SEC | Sanj K PatelCEO, Chair | Sell Plan | 98,934134,108 held (−42%) | $38.81 | $3.8M | +105.6% | — |
| Oct 22SEC | Sanj K PatelCEO, Chair | Sell Plan | 97,390111,794 held (−47%) | $38.83 | $3.8M | +105.5% | — |
| Oct 22SEC | Sanj K PatelCEO, Chair | Sell Plan | 39,331111,794 held (−26%) | $38.77 | $1.5M | +105.8% | — |
| Oct 22SEC | Michael R MegnaChief Accounting Officer | Sell Plan | 37,25540,281 held (−48%) | $38.72 | $1.4M | +106.0% | — |
| Oct 22SEC | Sanj K PatelCEO, Chair | Sell Plan | 22,314111,794 held (−17%) | $39.32 | $877K | +102.9% | — |
| Oct 22SEC | Michael R MegnaChief Accounting Officer | Sell Plan | 13,23527,046 held (−33%) | $39.31 | $520K | +103.0% | — |
| Oct 16SEC | Eben TessariCOO | Sell Plan | 11,81529,237 held (−29%) | $37.65 | $445K | +111.9% | — |
| Oct 16SEC | Eben TessariCOO | Sell Plan | 55328,684 held (−2%) | $37.99 | $21K | +110.0% | — |
| Oct 1SEC | Eben TessariCOO | Sell Plan | 42,00034,552 held (−55%) | $38.33 | $1.6M | +108.1% | — |
Insiders at Kiniksa Pharmaceuticals International, plc
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Sanj K PatelCEO, Chair | — | $39.4M | May 1, 2026 | — |
| John F. PaoliniChief Medical Officer | — | $8.0M | May 5, 2026 | — |
| Mark RagosaCFO | — | $5.6M | Mar 11, 2026 | — |
| Eben TessariCOO | — | $3.1M | Dec 17, 2025 | — |
| Barry D QuartDirector | — | $2.7M | Apr 29, 2026 | — |
| Michael R MegnaChief Accounting Officer | — | $2.6M | Sep 3, 2026 | — |
| G Bradley ColeDirector | — | $299K | Jul 31, 2026 | — |
| Ross MoatCOO | — | $195K | Apr 13, 2026 | — |
KNSA stock: common questions
Are Kiniksa Pharmaceuticals International, plc insiders buying KNSA stock?
In the past 12 months, 0 insiders reported open-market purchases of KNSA worth $0.
Are Kiniksa Pharmaceuticals International, plc insiders selling KNSA stock?
8 insiders reported sales worth $60.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is KNSA's 52-week range?
Over the past year KNSA has traded between $37.01 and $80.92. It last closed at $79.78 on Oct 9, 2026.